This research provides comprehensive evidence that chimeric SFT2D2‐TBX19 promotes prostate cancer progression by encoding the TBX19‐202 protein and stabilizing mitochondrial ATP synthase via ATP5F1A phosphorylation. Here, TBX19 is linked to prostate carcinoma.